VA-FLIR-SYSTEMS
7.1.2020 13:02:06 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) and ANSYS (NASDAQ: ANSS) are collaborating to deliver superior hazard detection capabilities for assisted driving and autonomous vehicles (AVs) — empowering automakers to deliver unprecedented vehicle safety. Through this collaboration, FLIR will integrate a fully physics-based thermal sensor into ANSYS’ leading-edge driving simulator to model, test, and validate thermal camera designs within an ultra-realistic virtual world. The new solution will reduce original equipment manufacturers’ (OEM) development time by optimizing thermal camera placement for use with tools such as automatic emergency braking (AEB), pedestrian detection, and within future AVs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005299/en/
Having the ability to test in virtual environments complements the existing systems available to FLIR customers and partners, including the FLIR automotive development kit (ADK™) featuring a FLIR Boson® thermal camera, the FLIR starter thermal dataset and the regional, city-specific thermal datasets. The FLIR thermal dataset programs were created for machine learning in advanced driver assistance development (ADAS), AEB, and AV systems.
The current AV and ADAS sensors face challenges in darkness or shadows, sun glare and inclement weather such as most fog. Thermal cameras, however, can effectively detect and classify objects in these conditions. Integrating FLIR Systems’ thermal sensor into ANSYS® VRXPERIENCE® enables simulation of thousands of driving scenarios across millions of miles in mere days. Furthermore, engineers can simulate difficult-to-produce scenarios where thermal provides critical data, including detecting pedestrians in crowded, low-contrast environments.
“By adding ANSYS’ industry-leading simulation solutions to the existing suite of tools for physical testing, engineers, automakers, and automotive suppliers can improve the safety of vehicles in all types of driving conditions,” said Frank Pennisi, President of the Industrial Business Unit at FLIR Systems. “The industry can also recreate corner cases that drivers can see every day but are difficult to replicate in physical environments, paving the way for improved neural networks and the performance of safety features such as AEB.”
“FLIR Systems’ recognizes the limitations of relying solely on gathering machine learning datasets in the physical world to make automotive thermal cameras as safe and reliable as possible for automotive uses,” said Eric Bantegnie, Vice president and General Manager at ANSYS. “Now with ANSYS solutions, FLIR can further empower automakers to speed the creation and certification of assisted-driving systems with thermal cameras.”
In addition to the city-specific data sets, FLIR has more than a decade of experience in the automotive industry. FLIR has provided more than 700,000 thermal sensors as part of its night vision warning systems for a variety of carmakers, including GM, Audi and Mercedes-Benz. Also, FLIR recently announced that its thermal sensor has been selected by Veoneer, a tier-one automotive supplier, for its level-four AV production contract with a top global automaker, planned for 2021.
FLIR Systems’ thermal-enhanced demonstration car, along with other innovative FLIR products, will be on display at the FLIR booth #8528 during the 2020 Consumer Electronics Show in Las Vegas, Nevada from January 6 - 10.
For more information on FLIR Systems’ automotive solutions, please visit https://www.flir.com/safercars .
About FLIR Systems, Inc.
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense, industrial, and commercial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005299/en/
Contact:
Media Contact: Tim McDowd (503) 498-3146 Tim.McDowd@flir.com
Investor Relations: Lasse Glassen Addo Investor Relations Phone: 424-238-6249 Email: lglassen@addoir.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom